These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 27372286)

  • 1. Imaging of hypoxia in mouse atherosclerotic plaques with (64)Cu-ATSM.
    Nie X; Randolph GJ; Elvington A; Bandara N; Zheleznyak A; Gropler RJ; Woodard PK; Lapi SE
    Nucl Med Biol; 2016 Sep; 43(9):534-542. PubMed ID: 27372286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/MRI of Hypoxic Atherosclerosis Using 64Cu-ATSM in a Rabbit Model.
    Nie X; Laforest R; Elvington A; Randolph GJ; Zheng J; Voller T; Abendschein DR; Lapi SE; Woodard PK
    J Nucl Med; 2016 Dec; 57(12):2006-2011. PubMed ID: 27390157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model.
    Oh M; Tanaka T; Kobayashi M; Furukawa T; Mori T; Kudo T; Fujieda S; Fujibayashi Y
    Nucl Med Biol; 2009 May; 36(4):419-26. PubMed ID: 19423010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
    Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
    J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers.
    Carlin S; Zhang H; Reese M; Ramos NN; Chen Q; Ricketts SA
    J Nucl Med; 2014 Mar; 55(3):515-21. PubMed ID: 24491409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
    Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
    Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
    Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
    J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques.
    Silvola JM; Saraste A; Laitinen I; Savisto N; Laine VJ; Heinonen SE; Ylä-Herttuala S; Saukko P; Nuutila P; Roivainen A; Knuuti J
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1294-301. PubMed ID: 22172786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
    O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry.
    Hansen AE; Kristensen AT; Jørgensen JT; McEvoy FJ; Busk M; van der Kogel AJ; Bussink J; Engelholm SA; Kjær A
    Radiat Oncol; 2012 Jun; 7():89. PubMed ID: 22704363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.
    Lohith TG; Kudo T; Demura Y; Umeda Y; Kiyono Y; Fujibayashi Y; Okazawa H
    J Nucl Med; 2009 Dec; 50(12):1948-53. PubMed ID: 19910425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma.
    Yoshii Y; Furukawa T; Kiyono Y; Watanabe R; Waki A; Mori T; Yoshii H; Oh M; Asai T; Okazawa H; Welch MJ; Fujibayashi Y
    Nucl Med Biol; 2010 May; 37(4):395-404. PubMed ID: 20447549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
    Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.
    Dehdashti F; Mintun MA; Lewis JS; Bradley J; Govindan R; Laforest R; Welch MJ; Siegel BA
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):844-50. PubMed ID: 12692685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning.
    Myerson RJ; Singh AK; Bigott HM; Cha B; Engelbach JA; Kim J; Lamoreaux WT; Moros E; Novak P; Sharp TL; Straube W; Welch MJ; Xu M
    Int J Hyperthermia; 2006 Mar; 22(2):93-115. PubMed ID: 16754595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
    Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
    J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.
    McCall KC; Humm JL; Bartlett R; Reese M; Carlin S
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e393-9. PubMed ID: 22727887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
    Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
    Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
    Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.
    Bradshaw TJ; Bowen SR; Jallow N; Forrest LJ; Jeraj R
    J Nucl Med; 2013 Nov; 54(11):1931-7. PubMed ID: 24042031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.